Chongqing Jiheng Pharmaceutical Co., Ltd. (SHE:002742)
China · Delayed Price · Currency is CNY 3.590
+0.090 (2.57%)
Aug 3, 2026, 3:04 PM CST
SHE:002742 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,456 | 3,092 | 1,776 | 1,460 | 1,961 | 3,188 | |
Market Cap Growth | 11.47% | 74.15% | 21.60% | -25.55% | -38.48% | 13.71% |
Enterprise Value | 3,006 | 4,940 | 3,656 | 3,299 | 3,641 | 4,748 |
Last Close Price | 3.59 | 4.52 | 4.11 | 3.38 | 4.54 | 7.38 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Forward PE | - | 16.30 | 16.30 | 16.30 | 16.30 | 16.30 |
PS Ratio | 3.04 | 3.44 | 1.49 | 0.72 | 0.94 | 1.28 |
PB Ratio | 10.65 | 12.92 | -7.75 | 2.62 | 1.98 | 2.43 |
P/TBV Ratio | - | - | - | - | - | 17.79 |
P/FCF Ratio | - | - | - | - | 402.35 | 77.69 |
P/OCF Ratio | - | - | - | - | 39.93 | 22.80 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.73 | 5.49 | 3.06 | 1.63 | 1.75 | 1.91 |
EV/EBITDA Ratio | - | - | - | 20.99 | 27.94 | 45.72 |
EV/EBIT Ratio | - | - | - | 107.38 | - | - |
EV/FCF Ratio | - | - | - | - | 747.05 | 115.70 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 2.30 | 2.20 | -7.64 | 3.18 | 1.69 | 1.19 |
Debt / EBITDA Ratio | 93.28 | - | - | 11.28 | 12.83 | 15.07 |
Debt / FCF Ratio | - | - | - | - | 342.92 | 38.14 |
Net Debt / Equity Ratio | 2.08 | 1.72 | -7.25 | 3.02 | 1.57 | 1.05 |
Net Debt / EBITDA Ratio | 84.38 | -33.24 | -99.15 | 10.70 | 11.92 | 13.34 |
Net Debt / FCF Ratio | -4.52 | -11.66 | -15.76 | -17.15 | 318.77 | 33.75 |
Asset Turnover | 0.44 | 0.47 | 0.37 | 0.52 | 0.49 | 0.54 |
Inventory Turnover | 3.66 | 3.98 | 4.10 | 6.27 | 6.47 | 6.34 |
Quick Ratio | 0.68 | 0.72 | 0.26 | 0.39 | 0.48 | 0.62 |
Current Ratio | 1.30 | 1.23 | 0.41 | 0.54 | 0.60 | 0.76 |
Return on Equity (ROE) | - | -8922.76% | -395.29% | -52.84% | -25.30% | -23.51% |
Return on Assets (ROA) | -2.82% | -3.44% | -2.53% | 0.49% | -0.03% | -0.61% |
Return on Invested Capital (ROIC) | -12.05% | -41.16% | -12.44% | 1.28% | -0.07% | -1.59% |
Return on Capital Employed (ROCE) | -9.50% | -12.00% | 93.80% | 4.60% | -0.20% | -2.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -14.06% | -13.57% | -36.62% | -30.96% | -16.21% | -10.46% |
FCF Yield | -4.32% | -1.14% | -5.94% | -6.72% | 0.25% | 1.29% |
Buyback Yield / Dilution | -9.74% | -0.53% | -58.96% | -0.22% | 0.57% | -0.01% |
Total Shareholder Return | -9.74% | -0.53% | -58.96% | -0.22% | 0.57% | -0.01% |